Evidence map›Paper›PMID 38834788›Full record

ArticleEuropean radiology2024

The diagnostic value of [

Peng Hou, Kaixiang Zhong, Wenliang Guo, Haiming Chen, Youcai Li, Miao Ke, Jie Lv, Shaoyu Liu, Huizhen Zhong, Yimin Fu and 6 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Peng Hou *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Kaixiang Zhong *Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Wenliang Guo *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510010, China.
Haiming Chen *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510010, China.
Youcai LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Miao KeDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Jie LvDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Shaoyu LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Huizhen ZhongDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Yimin FuDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Jielong LinDepartment of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Chunli LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510010, China.
Yingying GuDepartment of Respiratory Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510010, China.
Jilong QinDepartment of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China.
Cheng HongDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou, 510010, China. gyfyyhc@126.com.
Xinlu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510010, China. 71lu@163.com.ORCID http://orcid.org/0000-0003-1997-5687

Funding

the Natural Science Foundation of Guangdong Province, China 2022A1515010472
6 · The paper itself

Abstract

objectivesTo investigate the potential utility of [

methodsParticipants with clinically suspected PA malignancy were prospectively enrolled and underwent dual-tracer PET/CT ([

resultsThirty-three patients (18 males/15 females; mean age 53.1 ± 15.4 years) were enrolled. All 21 patients with malignant PA masses were FDG-positive (100%), whereas 20 out of 21 patients were FAPI-positive (95.2%). All 12 patients with benign PA masses were both negative in FDG and FAPI PET. The mean maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) of FAPI and FDG in malignant PA masses were significantly higher than those of benign masses. Although there was no significant difference in SUVmax between FDG and FAPI in malignant PA masses (11.36 vs. 9.18, p = 0.175), the TBR (liver) and TBR (left ventricle) were more favorable for FAPI than for FDG (13.04 vs. 5.17, p < 0.001); (median: 7.75 vs. 2.75, p = 0.007). Immunohistochemical analysis (n = 16) validated that the level of FAP expression corresponded strongly to the uptake of FAPI in PET/CT scans (r

conclusionsFAPI PET/CT is feasible in the diagnosis of PA masses. Although not superior to FDG PET/CT, FAPI PET/CT showed better target-to-background contrast. CLINICAL RELEVANCE STATEMENT: This study found that FAPI PET/CT is not superior to FDG PET/CT in diagnosing PA masses, but FAPI PET/CT displays better target-to-background contrast and more positive lesions, which may help improve disease management. KEY POINTS: Pulmonary malignancies lack specificity in clinical manifestations, laboratory tests, and routine imaging examinations. FAPI PET/CT is not diagnostically better than FDG PET/CT but displays better target-to-background contrast and more positive lesions. Dual-tracer PET/CT ([

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyPulmonary ArteryRadiopharmaceuticalsAdultAgedEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMaleMembrane ProteinsMiddle AgedPeptides, CyclicProspective StudiesVascular Neoplasmsalfatide IIEndopeptidasesFibroblast Activation Protein AlphaFluorodeoxyglucose F18Membrane ProteinsPeptides, CyclicRadiopharmaceuticalsDiagnosisFibroblast activation protein inhibitorPositron emission tomography-computed tomographyPulmonary arteryPulmonary artery sarcoma

Identifiers

PMID38834788

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.